PA8586001A1 - Derivados de indol útiles para el tratamiento de enfermedades - Google Patents

Derivados de indol útiles para el tratamiento de enfermedades

Info

Publication number
PA8586001A1
PA8586001A1 PA20038586001A PA8586001A PA8586001A1 PA 8586001 A1 PA8586001 A1 PA 8586001A1 PA 20038586001 A PA20038586001 A PA 20038586001A PA 8586001 A PA8586001 A PA 8586001A PA 8586001 A1 PA8586001 A1 PA 8586001A1
Authority
PA
Panama
Prior art keywords
diseases
treatment
derivatives useful
indol
derivatives
Prior art date
Application number
PA20038586001A
Other languages
English (en)
Inventor
Simon John Mantell
Mark Edward Bunnage
Alan Daniel Brown
Dustin Stephen Bryans
Paul Alan Glossop
Charlotte Alice Louise Lane
Russell Andrew Lewthwaite
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20020292513 external-priority patent/EP1407769A1/en
Priority claimed from EP03290069A external-priority patent/EP1440966A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of PA8586001A1 publication Critical patent/PA8586001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA INVENCION SE REFIERE A DERIVADOS DE INDOL Y A PROCEDIMIENTOS PARA LA PREPARACION DE INTERMEDIOS USADOS EN LA PREPARACION DE COMPOSICIONES QUE LOS CONTIENEN Y EL USO DE DICHOS DERIVADOS. LOS DERIVADOS DE INDOL SEGUN LA PRESENTE INVENCION SON UTILES EN NUMEROSAS ENFERMEDADES, TRASTORNOS Y AFECCIONES, EN PARTICULAR ENFERMEDADES, TRASTORNOS Y AFECCIONES INFLAMATORIAS, ALERGICAS Y RESPIRATORIAS.
PA20038586001A 2002-10-11 2003-10-10 Derivados de indol útiles para el tratamiento de enfermedades PA8586001A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20020292513 EP1407769A1 (en) 2002-10-11 2002-10-11 Indole derivatives as beta-2 agonists
EP03290069A EP1440966A1 (en) 2003-01-10 2003-01-10 Indole derivatives useful for the treatment of diseases

Publications (1)

Publication Number Publication Date
PA8586001A1 true PA8586001A1 (es) 2005-02-04

Family

ID=32095049

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038586001A PA8586001A1 (es) 2002-10-11 2003-10-10 Derivados de indol útiles para el tratamiento de enfermedades

Country Status (25)

Country Link
EP (1) EP1556034B1 (es)
JP (1) JP4490911B2 (es)
KR (1) KR20050047552A (es)
AP (1) AP2005003283A0 (es)
AR (1) AR041566A1 (es)
AT (1) ATE392206T1 (es)
AU (1) AU2003269316A1 (es)
BR (1) BR0315234A (es)
CA (1) CA2499314C (es)
CO (1) CO5550421A2 (es)
DE (1) DE60320439T2 (es)
EA (1) EA200500618A1 (es)
EC (1) ECSP055780A (es)
ES (1) ES2302938T3 (es)
IS (1) IS7751A (es)
MA (1) MA27452A1 (es)
MX (1) MXPA05003866A (es)
NO (1) NO20051406L (es)
OA (1) OA12938A (es)
PA (1) PA8586001A1 (es)
PE (1) PE20040775A1 (es)
PL (1) PL376396A1 (es)
TW (1) TW200424171A (es)
UY (1) UY28013A1 (es)
WO (1) WO2004032921A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
EP1460064A1 (en) * 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
GB0312832D0 (en) * 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005092841A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
KR20080036632A (ko) 2005-08-08 2008-04-28 아젠터 디스커버리 리미티드 바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
MEP9608A (en) 2006-03-20 2010-06-10 Pfizer Ltd Amine derivatives
US8258141B2 (en) 2006-04-21 2012-09-04 Novartis Ag Organic compounds
CN101553493B (zh) 2006-07-19 2012-07-04 阿斯利康(瑞典)有限公司 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
CN101610813A (zh) 2006-12-19 2009-12-23 阿斯利康(瑞典)有限公司 作为毒蕈碱受体拮抗剂的奎核醇衍生物
DK2104535T3 (da) 2007-01-10 2011-04-04 Irm Llc Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
AU2008214214B2 (en) 2007-02-09 2011-09-15 Irm Llc Compounds and compositions as channel activating protease inhibitors
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
PE20091096A1 (es) 2007-12-10 2009-08-25 Novartis Ag Compuestos organicos
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
NZ589091A (en) 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
RU2509077C2 (ru) 2008-05-27 2014-03-10 Астразенека Аб Феноксипиридиниламидные производные и их применение в лечении pde4-опосредованных болезненных состояний
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN102665715A (zh) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 治疗囊性纤维化和其他慢性疾病的组合物
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
PE20140378A1 (es) 2011-02-25 2014-03-28 Irm Llc Compuestos y composiciones como inhibidores de la trk
AR085509A1 (es) 2011-03-09 2013-10-09 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
ES2552538T3 (es) 2011-06-10 2015-11-30 Chiesi Farmaceutici S.P.A. Compuestos que tienen una actividad antagonista de un receptor muscarínico y agonista de un receptor beta-2 adrenérgico
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
KR102156441B1 (ko) 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
SG10201704032RA (en) 2012-12-06 2017-06-29 Chiesi Farm Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
AR099336A1 (es) 2014-02-17 2016-07-13 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
CN106458980A (zh) 2014-04-24 2017-02-22 诺华股份有限公司 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
CN106458966B (zh) 2014-04-24 2019-05-07 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
CA3139634A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CN114341132A (zh) 2019-08-28 2022-04-12 诺华股份有限公司 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途
AU2021296221A1 (en) 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ327795A3 (en) * 1993-06-14 1996-08-14 Pfizer Secondary amines
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
US5859044A (en) * 1996-07-31 1999-01-12 Pfizer Inc. β-adrenergic agonists

Also Published As

Publication number Publication date
UY28013A1 (es) 2004-04-30
TW200424171A (en) 2004-11-16
KR20050047552A (ko) 2005-05-20
DE60320439D1 (de) 2008-05-29
ECSP055780A (es) 2005-08-11
MXPA05003866A (es) 2005-06-22
EP1556034A1 (en) 2005-07-27
AP2005003283A0 (en) 2005-06-30
PL376396A1 (en) 2005-12-27
CA2499314C (en) 2010-08-24
CA2499314A1 (en) 2004-04-22
MA27452A1 (fr) 2005-07-01
NO20051406L (no) 2005-04-22
EA200500618A1 (ru) 2005-12-29
ES2302938T3 (es) 2008-08-01
IS7751A (is) 2005-03-17
WO2004032921A1 (en) 2004-04-22
PE20040775A1 (es) 2004-12-10
AR041566A1 (es) 2005-05-18
DE60320439T2 (de) 2009-05-20
BR0315234A (pt) 2005-08-23
OA12938A (en) 2006-10-13
ATE392206T1 (de) 2008-05-15
CO5550421A2 (es) 2005-08-31
JP4490911B2 (ja) 2010-06-30
AU2003269316A1 (en) 2004-05-04
JP2006511596A (ja) 2006-04-06
EP1556034B1 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
PA8604301A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
PA8632801A1 (es) Derivados de tetrahidronaftiridina
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
PA8622001A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
NI200300025A (es) Derivados de nicotinamida utiles como inhibidores de pde4.
PA8604201A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
PA8603001A1 (es) Compuestos utiles para el tratamiento de enfermedades
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
PA8566601A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4
CR8636A (es) Compuestos utiles para el tratamiento de enfermedades
CR7784A (es) Derivados de indol utiles para el tratamiento de enfermedades
CR7835A (es) Uso de levocetiricina para el tratamiento de la rinitis alergica persistente
DOP2003000732A (es) Derivados de indol utiles para el tratamiento de enfermedades
SV2005002056A (es) Derivados de formamida para el tratamiento de enfermedades ref. pc32168a
PA8626401A1 (es) Compuestos útiles para el tratamiento de enfermedades
PA8627101A1 (es) Compuestos para el tratamiento de enfermedades
DOP2005000043A (es) Compuestos para el tratamiento de enfermedades
GT200500056A (es) Compuestos utiles para el tratamiento de enfermedades
ECSP066700A (es) Derivados de sulfonamida para el tratamiento de enfermedades
CR8513A (es) Derivados de sulfonamida para el tratamiento de enfermedades
UY28156A1 (es) Nuevas composiciones farmacéuticas basadas en nuevos anticolinérgicos e inhibidores de la quinasa del egfr
DOP2004000921A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades